Abstract
Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs. In the case of antiarrhythmic drugs, the narrow therapeutic margin of most of these agents and a direct relationship between their pharmacological effects and plasma concentrations would justify more widespread use of monitoring. Optimum plasma concentration ranges have been described for lignocaine (lidocaine), procainamide, quinidine and, more recently, also for disopyramide, mexiletine, tocainide and other new antiarrhythmics. A critical analysis of the original data shows, however, that therapeutic and toxic levels are not so well defined as often assumed: small numbers of patients, marked interindividual variability, sometimes inadequate documentation of arrhythmias and lack of standardised blood sampling characterise many of these studies. Uncertainty about the reliability of concentration-effect relationships also arises when active drug metabolites are identified or there are marked concentration-dependent changes of drug protein-binding. In addition, abolition of various types of arrhythmias might require different drug concentrations. Nevertheless, therapeutic monitoring can be of practical value in patients with life-...Continue Reading
Citations
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·C A Jamis-DowJ M Collins
Apr 1, 1989·European Journal of Drug Metabolism and Pharmacokinetics·C KöppelF Martens
Sep 1, 2005·Pediatric Cardiology·V V DimasK E Ward
Jan 1, 1988·Journal of the American College of Cardiology·R LatiniA Volpi
Nov 22, 2012·Journal of Chromatographic Science·Yi ZhouXue-Hua Jiang
Mar 1, 1991·British Journal of Clinical Pharmacology·K FattingerF Follath
Jul 10, 2002·Clinical Pharmacokinetics·Reza MehvarMajid Vakily
Nov 22, 2007·Clinical Pharmacokinetics·Ulrich Klotz
Nov 1, 1989·Medical Toxicology and Adverse Drug Experience·C P Denaro, N L Benowitz
Nov 1, 1984·British Journal of Clinical Pharmacology·J E Bredesen, P Kierulf
Dec 1, 1986·Journal of Veterinary Pharmacology and Therapeutics·M G PapichC A Davis
Sep 1, 1986·British Journal of Clinical Pharmacology·J E Bredesen, P Kierulf
Jan 9, 2004·Infectious Disease Clinics of North America·John Turnidge
Sep 1, 1996·Clinical Pharmacology and Therapeutics·S LaganièreI McGilveray
Jul 1, 1993·Biomedical Chromatography : BMC·S G JiP Li
Feb 1, 1987·Journal of Pharmacokinetics and Biopharmaceutics·M YasuharaC Kawai
Jan 1, 1989·British Journal of Pharmacology·Y HashimotoR Hori
Apr 1, 1986·Drug Intelligence & Clinical Pharmacy·B J Schrader, J L Bauman
Mar 1, 1996·The Annals of Pharmacotherapy·R LatiniU Guiducci
Dec 22, 2020·Journal of Cardiothoracic and Vascular Anesthesia·Daniel J KatzJordan E Goldhammer
Jul 13, 1984·Journal of Chromatography·O Grech-Bélanger